Wire Stories

Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

V940-001 is the first Phase 3 study of a planned comprehensive clinical development program being initiated following the positive primary…

2 years ago

UMC Reports Second Quarter 2023 Results

Company’s differentiating specialty technologies accounted for 59% of Q2 revenue Solid 22/28nm business momentum lifted contribution to 29% Second Quarter…

2 years ago

Ant Group Advances Privacy-Preserving Computing Research in Collaboration with NTU Singapore

SINGAPORE--(BUSINESS WIRE)--Ant Group and Nanyang Technological University, Singapore (NTU Singapore) have begun a research collaboration to explore privacy-preserving computing technology…

2 years ago

Capcom Makes Swordcanes Studio Co., Ltd. a Wholly-Owned Subsidiary Through Share Acquisition

OSAKA, Japan--(BUSINESS WIRE)--#Capcom--Capcom Co., Ltd. (TOKYO:9697) today announced that it has acquired all shares in Swordcanes Studio Co., Ltd. (Swordcanes),…

2 years ago

Wipro Recognized as ‘Leader’ in ISG Provider Lens™ Network – Software Defined Solutions and Services Report for Singapore and Malaysia

Wipro is leading with its broad range of network offerings related to Software Defined Networking in Singapore & Malaysia SINGAPORE…

2 years ago

The 2023 Hakka Expo Set to Kick off in Taoyuan

TAOYUAN, Taiwan--(BUSINESS WIRE)--This year, the Hakka Expo will be held in Taoyuan City from Aug. 11 through Oct. 15. The…

2 years ago

Guidewire Celebrates First Year of Bengaluru Office

BENGALURU, India--(BUSINESS WIRE)--$GWRE #cloudcomputing--Guidewire (NYSE: GWRE) celebrated the one-year anniversary of its office in Bengaluru, India. The staff in the…

2 years ago

Toshiba Materials’ Major Investment in Second Production Facility Will Boost Silicon Nitride Ball Production

YOKOHAMA, Japan--(BUSINESS WIRE)--Toshiba Materials Co., Ltd. (President & CEO: Takao Shirai) today announced a major investment in a new production…

2 years ago

AmbioPharm, a Global Peptide CDMO

Global Peptide CDMO with China and US Manufacturing Facilities SHANGHAI--(BUSINESS WIRE)--#cGMP--AmbioPharm, a worldwide leader in peptide API CDMO services, continues…

2 years ago

InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases,…

2 years ago